News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
Otsuka Pharmaceutical Co., Ltd. announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd. and its U.S. subsidiary, Sumitomo Pharma America, Inc.
Otsuka’s Economic and Health Impact in the United States report is now available. The report highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., McQuade Center for Strategic Research & Development, and Otsuka Precision Health, Inc., formerly known as Otsuka Digital Health, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical, Co. Ltd., and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).
Otsuka Pharmaceutical Development & Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd. announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).